Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment for Men with Hypogonadism
Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan® (transdermal testosterone gel 2%), a testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. The Netherlands acted as Reference Member State (RMS) on behalf of all 31 European Economic Areas (EEA) countries.1
“Men suffering from hypogonadism symptoms, including erectile dysfunction and fatigue, often remain untreated due to barriers that delay diagnosis and lack of treatment options,” said Per Falk, Executive Vice President and Chief Science Officer, Ferring Pharmaceuticals. “Ferring is committed to delivering innovative healthcare solutions to treat a number of male urologic conditions. With the positive outcome of the DCP, hypogonadal patients in many European countries will soon have access to a convenient treatment to normalise testosterone and relieve symptoms.”
Testavan’s fast-drying gel formulation is based on Ferring’s Advanced Skin Technology (F.A.S.T.), a proprietary transdermal gel technology, which enhances bioavailability of testosterone through the skin. Testavan’s low dose and volume, in addition to its unique hands-free applicator, were designed to ensure patient convenience. The hands-free applicator may lower the risk of transference of testosterone skin residue from the patient to others.8-10
In phase III trials, men treated with Testavan achieved normalised testosterone levels by month three, with improvements in quality of life and fatigue scores over three months, and early and sustained increase in erectile function score at one and three months. Assessment measures included testosterone responder rate, defined as the percentage of subjects achieving normalised levels of testosterone (300-1050 ng/dL); the Multidimensional Assessment of Fatigue (MAF); general well-being assessment (Short Form 12 Health Survey, SF-12); International Index of Erectile Function (IIEF).
About male hypogonadism
Male hypogonadism is a condition characterised by low levels or absence of testosterone due to certain medical conditions, and signs and symptoms of testosterone deficiency. Male hypogonadism is reported to have an incidence of 2-6% in men aged 40-79 years and becomes more common with age.3 There is a substantial quality of life and clinical burden associated with hypogonadism in men, and can be associated with comorbidities such as diabetes, metabolic syndrome, cardiovascular diseases, and adverse bonehealth.3,11-14
Testavan, the new 2% testosterone gel, uses a proprietary hydroalcoholic and highly viscous topical formulation. The product is homogeneous, transparent and nonstaining, and comes in a metered dose dispenser that includes a hands-free cap applicator for precise dispensing and application. The starting dose is 23 mg testosterone, delivered by one pump actuation, contained in 1.15 g of gel, and the highest dose is 3.45 g of gel containing 69 mg testosterone (delivered by 3 pump actuations).1
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
# # #
1 Ferring Pharmaceuticals. Data on file 2018.
2 Nieschlag E, Behre HM (eds). Andrology: male reproductive health and dysfunction. 3rd edn. Heidelberg: Springer, 2010.
3 Dohle G. et al. Guidelines on Male Hypogonadism. EAU guidelines 2017. Available at: http://uroweb.org/guideline/male-hypogonadism/#note_4 Last accessed: March 2018
4 Belkoff L. et al. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open label studies. Andrologia 2018 Feb;50(1). doi: 10.1111/and.12801. Epub 2017 Mar 10.
5 Arver S. et al. A new 2% testosterone gel formulation: A comparison with currently available topical preparations. In Press. Andrology 2018.
6 Cunningham G et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr Pract 2017;23(5):557-565.
7 Testavan Summary of Product Characteristics. Ferring Pharmaceuticals.
8 Alberti I. et al. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv 2005;2:935-950.
9 Olsson H. et al. Pharmacokinetics and Bioavailability of a New Testosterone Gel Formulation in Comparison to Testogel in Healthy Men. Clin Pharmacol Drug Dev 2014;3(5):358-64.
10 Efros M., Carrara D., Neijber A. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies. Andrologia 2016;48(6):637-645.
11 Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14(3):226-234.
12 García-Cruz E. et al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. J Sex Med 2013;10(10);2529-2538.
13 Rodriguez-Tolrà J. et al. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology 2013;1(4):570-575.
14 Zarotsky V. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2014;2(6):819-834.
Head of Corporate Communications
+41 583010952 (direct)
+41 791910632 (mobile)
Senior Manager, Corporate Communications
+41 584514023 (direct)
+41 791910486 (mobile)
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Andersen Global Expands Presence in Portugal with CNA - Curado, Nogueira & Associados19.4.2018 13:30 | Pressemelding
Andersen Global expands its presence in Portugal through a Collaboration Agreement with CNA - Curado, Nogueira & Associados (CNA), a law firm located in Porto. The addition of CNA as a collaborating firm of Andersen Global is part of the firm’s growth strategy in Europe. The CNA team is led by Founding Partners Luisa Curado, Teresa Nogueira and Carla Malhão, who founded the firm in 2005. “We recognize that Andersen Global shares our same commitment to transparency, stewardship, and best-in-class client service, and not only are these values consistent with our own, we also appreciate working with like-minded professionals and understand its benefit to our clients,” said Teresa. “Additionally, we are excited to be part of an international operating tax and legal firm.” Global Chairman and Andersen Tax LLC CEO, Mark Vorsatz, added, “The team at CNA is an excellent fit with our organization and Luisa, Teresa and Carla bring with them the experience and values that continue to play a signi
Amazon Studios Greenlights Utopia, Signs Gillian Flynn to Overall Deal19.4.2018 13:00 | Pressemelding
(NASDAQ: AMZN)— Amazon Studios announced today that it has greenlit a straight-to-series order for Utopia, a nine-episode series from award-winning Gillian Flynn, the best-selling author and screenwriter of Golden Globe nominated Gone Girl and HBO’s highly anticipated Sharp Objects. Flynn has also inked an overall deal with Amazon Studios across television, marking Utopia as the first project. Utopia will be available exclusively on Prime Video in more than 200 countries and territories. Utopia is based on the British series of the same name written by Dennis Kelly. The series is a co-production between Endemol Shine North America and Kudos, an Endemol Shine Group UK production studio, and Amazon Studios. A group of young adults, who meet online, are mercilessly hunted by a shadowy deep state organization after they come in to possession of a near mythical cult underground graphic novel – they discover the conspiracy theories in the comic’s pages may actually be real and are forced in
Yourtyres.co.uk at The Tire Cologne 2018: Concepts for Linking Online and Offline Business19.4.2018 12:47 | Pressemelding
Delticom AG/Yourtyres.co.uk. At this year’s Tire Cologne trade fair, Yourtyres.co.uk will be presenting its partnership model, which focuses on the linking of online and offline trade. Yourtyres.co.uk is the online wholesale shop from Europe’s largest tyre retailer, Delticom. From 29th May to 1st June, visitors to the fair can learn how workshops and stationary tyre retailers are able to benefit from the increasing amount of online trade without having to give up their independence. This is because Yourtyres.co.uk offers its wholesale customers excellent terms of purchase and high flexibility. There are no minimum purchase levels, and customers are not obliged to stock specific brands. There are also no contract costs or commissions. Using the Yourtyres.co.uk website and placing orders are completely free of charge. Customers benefit from the shop’s wide range of car, truck and motorbike tyres, as well as high availability all year round thanks to Delticom’s in-house warehousing and in
Flowsion A/S Wins Horizon 2020 SME Instrument Grant for Automatic Glucose Control in Intensive Care Medicine19.4.2018 11:48 | Pressemelding
Flowsion, the Denmark-based developer of continuous blood glucose systems for intensive care medicine, has won a prestigious European Commission Horizon 2020 SME Instrument award. The grant was awarded to assist in the development of an innovative automatic blood glucose control system, Glucostat, developed by Flowsion. Glucostat is expected to reduce mortality, morbidity, length of stay and treatment costs dramatically for intensive care patients compared to existing technologies. “It’s a welcome validation of our innovative, patented technology and a confirmation that we are addressing a really significant problem with a globally-relevant market opportunity,” said Hans Jorgen Pedersen, CEO of Flowsion. “Flowsion has already performed clinical studies with the system so we now that Glucostat will fulfil the demands of the intensive care units.” With 5-8 % success rate the European Innovation Council SME Instrument awards are exceptionally competitive, and only 3018 companies across Eu
Nexperia Secures $800M Financing to Fund Future Growth Plans19.4.2018 09:33 | Pressemelding
Nexperia, the global leader in discretes, logic and MOSFET devices, today announced the successful completion of a refinancing of its current facilities with USD 800 million equivalent of senior credit facilities. This includes a significant proportion of Revolving Credit facility. The proceeds will be used to refinance existing outstanding debt and for Capex expenditure to fund future growth. The facilities were arranged by Bank of America Merrill Lynch and HSBC, acting as Global Coordinators, and were syndicated by a group of nine global banks. The refinancing is fully supported by JAC Capital and Wise Road Capital, Nexperia’s two main shareholders, and provides a flexible financing package at very attractive terms to support the further growth of Nexperia going forward. Comments from Frans Scheper, Nexperia’s CEO: “This is the first time that Nexperia has approached the financial markets as an independent company, so we are very pleased with the enthusiastic response. Refinancing th
Grundig – Redefining Kitchen Design and Technology19.4.2018 09:19 | Pressemelding
UNLEASH YOUR GOURMET CAPABILITIES WITH GRUNDIG’S GOURMET CHEF™ OVEN This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005580/en/ (Photo: Grundig) Grundig’s Gourmet Chef™ Oven makes cooking elaborate, delicious meals easier than ever before. The oven’s intuitive design and innovative technology combine to simplify cooking and cleaning processes, inspire culinary creativity, and produce exquisite results. Equipped with advanced connected technologies and sensors, it allows users to precisely control the temperature of their food as it cooks to ensure the best results. This includes a high temperature moisture sensor, a temperature control sensor and BLDC motor, an integrated camera and a multipoint meat probe. Cleaning up after your culinary creation couldn’t be easier for users, with the oven fitted with advanced automatic self cleaning, including water and high-pressure steam cleaning, The Gourmet Chef™ elegant and sophis